<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01890577</url>
  </required_header>
  <id_info>
    <org_study_id>20110243</org_study_id>
    <nct_id>NCT01890577</nct_id>
  </id_info>
  <brief_title>Study of South African Dialysis Patients</brief_title>
  <official_title>An Observational Study of South African Dialysis Patients Treated With Aranesp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational study to describe the treatment of anaemia in patients with chronic kidney
      disease, who are receiving dialysis treatment at selected study centres in South Africa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicentre, prospective, observational study will describe the treatment and clinical
      outcomes of of dialysis patients in South Africa. No formal hypothesis will be tested in this
      descriptive study. Eligible subjects will be receiving either peritoneal or haemodialysis,
      will have received Aranesp therapy between 3 and 6 months prior to enrolment into the study,
      do not need to be receiving Aranesp at the time of enrolment and will be followed for up to
      12 months after commencement of Aranesp. Data to be collected includes ESA therapies, iron
      usage, relevant concomitant therapies, haemoglobin concentrations, other relevant clinical
      laboratory parameters and red cell transfusions.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to slow enrolment with no reasonable expectation of attaining a
    meaningful sample size
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Haemoglobin Concentration</measure>
    <time_frame>Each 4-week period for the duration of the study period (15 months)</time_frame>
    <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Excursions</measure>
    <time_frame>Over the 15-month observation period</time_frame>
    <description>Hemoglobin excursions defined as hemoglobin &lt;10g/dL and &gt;12g/dL. Due to the premature termination of the study no outcome measure data were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Within the Range 10-12 g/dL Over Time</measure>
    <time_frame>On a continuous basis over the 15-month observation period</time_frame>
    <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoiesis Stimulating Agent (ESA) Usage</measure>
    <time_frame>Over the 15-month observation period</time_frame>
    <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESA/Aranesp Dose Ratio</measure>
    <time_frame>Day of commencement of Aranesp</time_frame>
    <description>Ratio of the calculated mean weekly dose equivalent of an ESA administered immediately prior to conversion to treatment with Aranesp, to the calculated mean weekly dose equivalent of the first dose of Aranesp administered at commencement. Not applicable to participants who were ESA-naive at time of Aranesp commencement.
Due to the premature termination of the study no outcome measure data were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron Therapy Use</measure>
    <time_frame>Over the 15-month observation period</time_frame>
    <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Concomitant Therapies: Immunosuppressants, Cardiovascular Medications, Secondary Hypoparathyroidism Medications, Anti-retroviral Therapy</measure>
    <time_frame>At each 12-week interval over the observation period</time_frame>
    <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein, Albumin, Transferrin Saturation and Serum Ferritin Concentration</measure>
    <time_frame>Over the 15-month observation period</time_frame>
    <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Red Blood Cell Transfusions</measure>
    <time_frame>Over the 15-month observation period</time_frame>
    <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalisations</measure>
    <time_frame>Over the 15-month observation period</time_frame>
    <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Kidney Disease, Receiving Dialysis</condition>
  <arm_group>
    <arm_group_label>Study population</arm_group_label>
    <description>Single cohort of dialysis patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aranesp</intervention_name>
    <description>Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.</description>
    <arm_group_label>Study population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients receiving dialyis at South African study centres and having received at
        least one dose of Aranesp
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients undergoing chronic haemodialysis or peritoneal dialysis

          -  Commenced Aranesp therapy 3-6 months prior to enrolment

          -  Erythropoiesis stimulating agent (ESA) naive or treated with another ESA prior to
             commencing Aranesp

          -  Informed consent obtained

        Exclusion Criteria:

          -  Received Aranesp in an interventional study within 6 months prior to start of
             observation period

          -  Receive investigational product during the observation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glenwood</city>
        <state>KwaZulu-Natal</state>
        <zip>4083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Umhlanga Rocks</city>
        <state>KwaZulu-Natal</state>
        <zip>4320</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7800</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kimberley</city>
        <zip>8300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lenasia</city>
        <zip>1821</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roodepoort</city>
        <zip>1709</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2013</study_first_posted>
  <results_first_submitted>March 31, 2015</results_first_submitted>
  <results_first_submitted_qc>March 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2015</results_first_posted>
  <last_update_submitted>June 8, 2016</last_update_submitted>
  <last_update_submitted_qc>June 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Erythropoiesis stimulating agent</keyword>
  <keyword>South Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aranesp®</title>
          <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set (FAS) consists of all patients enrolled into the study after commencing Aranesp® therapy amd with reported data</population>
      <group_list>
        <group group_id="B1">
          <title>Aranesp®</title>
          <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age data were available for 27 participants</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender data were available for 27 participants</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race data were available for 27 participants</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White/caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Hemoglobin Concentration</title>
          <description>Data were available for 11 participants</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Aranesp Route</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Intravenous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Aranesp Dose</title>
          <units>µg/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Haemoglobin Concentration</title>
        <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
        <time_frame>Each 4-week period for the duration of the study period (15 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aranesp®</title>
            <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Haemoglobin Concentration</title>
          <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Excursions</title>
        <description>Hemoglobin excursions defined as hemoglobin &lt;10g/dL and &gt;12g/dL. Due to the premature termination of the study no outcome measure data were analyzed.</description>
        <time_frame>Over the 15-month observation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aranesp®</title>
            <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Excursions</title>
          <description>Hemoglobin excursions defined as hemoglobin &lt;10g/dL and &gt;12g/dL. Due to the premature termination of the study no outcome measure data were analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Within the Range 10-12 g/dL Over Time</title>
        <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
        <time_frame>On a continuous basis over the 15-month observation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aranesp®</title>
            <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Within the Range 10-12 g/dL Over Time</title>
          <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythropoiesis Stimulating Agent (ESA) Usage</title>
        <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
        <time_frame>Over the 15-month observation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aranesp®</title>
            <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythropoiesis Stimulating Agent (ESA) Usage</title>
          <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ESA/Aranesp Dose Ratio</title>
        <description>Ratio of the calculated mean weekly dose equivalent of an ESA administered immediately prior to conversion to treatment with Aranesp, to the calculated mean weekly dose equivalent of the first dose of Aranesp administered at commencement. Not applicable to participants who were ESA-naive at time of Aranesp commencement.
Due to the premature termination of the study no outcome measure data were analyzed.</description>
        <time_frame>Day of commencement of Aranesp</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aranesp®</title>
            <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>ESA/Aranesp Dose Ratio</title>
          <description>Ratio of the calculated mean weekly dose equivalent of an ESA administered immediately prior to conversion to treatment with Aranesp, to the calculated mean weekly dose equivalent of the first dose of Aranesp administered at commencement. Not applicable to participants who were ESA-naive at time of Aranesp commencement.
Due to the premature termination of the study no outcome measure data were analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Iron Therapy Use</title>
        <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
        <time_frame>Over the 15-month observation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aranesp®</title>
            <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Iron Therapy Use</title>
          <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Concomitant Therapies: Immunosuppressants, Cardiovascular Medications, Secondary Hypoparathyroidism Medications, Anti-retroviral Therapy</title>
        <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
        <time_frame>At each 12-week interval over the observation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aranesp®</title>
            <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Concomitant Therapies: Immunosuppressants, Cardiovascular Medications, Secondary Hypoparathyroidism Medications, Anti-retroviral Therapy</title>
          <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-Reactive Protein, Albumin, Transferrin Saturation and Serum Ferritin Concentration</title>
        <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
        <time_frame>Over the 15-month observation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aranesp®</title>
            <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>C-Reactive Protein, Albumin, Transferrin Saturation and Serum Ferritin Concentration</title>
          <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Red Blood Cell Transfusions</title>
        <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
        <time_frame>Over the 15-month observation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aranesp®</title>
            <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Red Blood Cell Transfusions</title>
          <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalisations</title>
        <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
        <time_frame>Over the 15-month observation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aranesp®</title>
            <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalisations</title>
          <description>Due to the premature termination of the study no outcome measure data were analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <desc>Only serious and non-serious adverse drug reactions which in the Investigator’s opinion are causally related to Aranesp were collected during this observational study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aranesp®</title>
          <description>Participants receiving Aranesp® (darbepoetin alfa) for at least 3 months prior to enrolment and according to the local prescribing guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

